PMID- 31062637
OWN - NLM
STAT- MEDLINE
DCOM- 20200220
LR  - 20200220
IS  - 1532-4311 (Electronic)
IS  - 0882-0139 (Linking)
VI  - 48
IP  - 8
DP  - 2019 Nov
TI  - Aberrant Phenotype and Function of Dendritic Cells in Adult B Lineage Acute 
      Lymphoblastic Leukemia.
PG  - 781-793
LID - 10.1080/08820139.2019.1610428 [doi]
AB  - Dendritic cells (DCs) play a major role in regulating immune responses, but the 
      aberrant phenotype and function of defective DCs in adult acute lymphoblastic 
      leukemia (ALL) remain unclear. Here, B lineage ALL (B-ALL) patients were divided 
      into groups according to different standards. By course of disease: newly 
      diagnosed (ND), complete remission (CR), consolidation (CONS). By stratification: 
      high risk (HR), standard risk (SR). By minimal residual disease (MRD): MRD 
      positive(MRD+), MRD negative (MRD-). The proportion of plasmacytoid DC(pDC) and 
      myeloid DC(mDC) were compared within these standards. The costimulatory molecule 
      levels of pDC, mDC in ND and CR were measured and the function of peripheral 
      blood monocyte-derived DC(MoDC)s were examined. We found proportions of pDC and 
      mDC in ND were both lower compared to control group and gradually increased after 
      CR. In HR and MRD+, the proportions were also lower compared to SR and MRD- at CR 
      stage, respectively; but there were no difference between these comparisons when 
      newly diagnosed. In ND, both CD80, CD86 levels in pDC, mDC were higher while the 
      levels in activated MoDCs were lower when compared to control and CR group, 
      respectively. The dextran uptake of MoDCs, T cell proliferation promoting 
      ability, IL-12, BAFF, INF-alpha levels in supernatant and their mRNA relative 
      expression in activated MoDCs in ND were also lower than those in control and CR 
      group. So, DCs in B-ALL display suppressed status in phenotype and function，which 
      would be gradually restored after effective chemotherapy. pDC and mDC could 
      respond to patient condition, DCs proportion may be useful for monitoring disease 
      progression.
FAU - Zhou, Zhenhai
AU  - Zhou Z
AUID- ORCID: 0000-0003-3697-2138
AD  - Department of Hematology, The First Affiliated Hospital, Sun Yat-sen University , 
      Guangzhou , Guangdong , P.R. China.
FAU - Lin, Wanyi
AU  - Lin W
AD  - Department of Blood Transfusion, The First Affiliated Hospital, Sun Yat-sen 
      University , Guangzhou , Guangdong , P.R. China.
FAU - Li, Xiaoyin
AU  - Li X
AD  - Department of Radiology Intervention, The First Affiliated Hospital, Sun Yat-sen 
      University , Guangzhou , Guangdong , P.R. China.
FAU - Huang, Yuling
AU  - Huang Y
AD  - Department of Hematology, The First Affiliated Hospital, Sun Yat-sen University , 
      Guangzhou , Guangdong , P.R. China.
FAU - Ren, Jun
AU  - Ren J
AD  - Department of Blood Transfusion, The First Affiliated Hospital, Sun Yat-sen 
      University , Guangzhou , Guangdong , P.R. China.
FAU - Gao, Yixin
AU  - Gao Y
AD  - Department of Blood Transfusion, The First Affiliated Hospital, Sun Yat-sen 
      University , Guangzhou , Guangdong , P.R. China.
FAU - Li, Juan
AU  - Li J
AD  - Department of Hematology, The First Affiliated Hospital, Sun Yat-sen University , 
      Guangzhou , Guangdong , P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20190507
PL  - England
TA  - Immunol Invest
JT  - Immunological investigations
JID - 8504629
RN  - 0 (B-Cell Activating Factor)
RN  - 0 (Interferon-alpha)
RN  - 0 (TNFSF13B protein, human)
SB  - IM
MH  - Adult
MH  - B-Cell Activating Factor/genetics/immunology/metabolism
MH  - Cell Proliferation/genetics
MH  - Cells, Cultured
MH  - Dendritic Cells/*immunology/metabolism
MH  - Female
MH  - Gene Expression/immunology
MH  - Humans
MH  - Interferon-alpha/genetics/immunology/metabolism
MH  - Lymphocyte Activation/genetics/*immunology
MH  - Male
MH  - Middle Aged
MH  - Monocytes/*immunology/metabolism
MH  - Neoplasm, Residual/genetics/immunology/metabolism
MH  - Phenotype
MH  - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics/*immunology/therapy
MH  - Remission Induction
OTO - NOTNLM
OT  - Dendritic cells
OT  - acute lymphoblastic leukemia
OT  - costimulatory molecules
OT  - minimal residual disease
EDAT- 2019/05/08 06:00
MHDA- 2020/02/23 06:00
CRDT- 2019/05/08 06:00
PHST- 2019/05/08 06:00 [pubmed]
PHST- 2020/02/23 06:00 [medline]
PHST- 2019/05/08 06:00 [entrez]
AID - 10.1080/08820139.2019.1610428 [doi]
PST - ppublish
SO  - Immunol Invest. 2019 Nov;48(8):781-793. doi: 10.1080/08820139.2019.1610428. Epub 
      2019 May 7.